Eli Lilly’s weight-loss drug no longer in shortage, FDA says. The announcement is a blow to the compounding pharmacies that have made cheaper, off-brand versions of the medication.

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when patients ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

A federal judge has sided with the U.S. Food and Drug Administration over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...

All doses of Eli Lilly’s weight loss drugs Zepbound and Mounjaro are available in the United States after more than a year of being in shortage, according to the Food and Drug Administration’s ...

All doses of Eli Lilly’s weight loss drugs Zepbound and Mounjaro are available in the U.S. after more than a year of being in shortage, according to the FDA's medication shortage database.

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...

Eli Lilly and its rival Novo Nordisk, which makes the diabetes drug Ozempic and its weight-loss version Wegovy, have been in a fierce battle against the emerging industry making copies of their drugs.